Acute Exacerbation of Chronic Obstructive Airways Disease Clinical Trial
Official title:
β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation
The effectiveness of β2-agonists in the treatment of exacerbations of COPD is already established. The purpose of this study is to compare the effectiveness of the β2-agonists alone in nebulization with the association β2-agonists + Ipratropium bromide in the treatment of an acute exacerbation of COPD consulting the emergency departement based on the clinical and arterial blood gas.
It is a prospective study and randomized performed in patients admitted to the emergency departement for acute exacerbation of COPD. The patients were divided in two groups: Group Terbutaline/Ipratropium Bromide; received Terbutaline + Ipratropium bromide in nebulization and Group Terbutaline received Terbutaline alone in nebulization) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02171338 -
Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections
|
Phase 4 | |
| Completed |
NCT01291303 -
Optimization of Ventilator Setting for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
|
N/A | |
| Recruiting |
NCT01513655 -
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation
|
Phase 4 |